Product Details
| Clone: | 1G11 |
| |
| Host: | Mouse |
| |
| Isotype: | IgG1 |
| |
| Immunogen: | Synthetic peptide corresponding to a portion of Rictor. |
| |
| UniProt ID: | Q6R327 |
| |
| Species reactivity: | Human, Mouse, Rat
|
| |
| Applications: | WB
|
| |
| Recommended Dilutions/Conditions: | Western Blot (0.5µg/ml, ECL)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application. |
| |
| Application Notes: | Detects a band of ~190kDa by Western blot. |
| |
| Purity Detail: | Thiophilic adsorption and size exclusion chromatography purified. |
| |
| Formulation: | Lyophilized from 1ml of 2x PBS containing 0.09% sodium azide, PEG, and sucrose. |
| |
| Reconstitution: | Reconstitute with 1ml water (15 minutes at room temperature). |
| |
| Use/Stability: | Stable at -80°C up to 1 year, at 4°C up to 3 months. |
| |
| Handling: | Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -80°C. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | The mTOR (mammalian target of rapamycin) pathway coordinates nutrient signals with growth factor dependent signaling. mTOR is organized in two independent protein complexes, mTORC1 and mTORC2. The mTORC1 complex containing mTOR, GβL/mLST8 and Raptor is sensitive to rapamycin, while the mTORC2 complex containing mTOR, GβL/mLST8, SIN1, and Rictor is rapamycin insensitive. The mTOR/Rictor complex phosphorylates numerous substrates associated with regulation of the actin cytoskeleton, and is also responsible for phosphorylation of Akt/PKB at Ser473, a critical step in Akt activation. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Western blot analysis of serum starved cancer cells probed with Rictor mAb (1G11); HeLa (1), HepG2 (2), HEK293 (3), SH-SY5Y (4), MDCK (5), PC12 (6), CTM93 (7) Neuro 2A (8), NIH-3T3 (9).
Please mouse over
Product Literature References
mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells: N. Komatsu, et al.; Oncogene
34, 5607 (2015),
Application(s): Western Blotting,
Abstract;
Related Products
